XML 27 R6.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Total Radnet, Inc.'s Equity
Common Stock
Common Stock
DeepHealth, Inc.
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2019     50,314,328          
Beginning balance, value at Dec. 31, 2019 $ 233,139 $ 151,685 $ 5   $ 262,865 $ (8,026) $ (103,159) $ 81,454
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of common stock under the equity compensation plan (in shares)     453,817 4,338        
Stock-based compensation expense 10,203 10,203     10,203      
Issuance of common stock for sale of unregistered securities for the DeepHealth acquisition (in shares)     823,615          
Issuance of common stock for sale of unregistered securities for the DeepHealth acquisition 33,011 33,011     33,011      
Distributions paid to noncontrolling interests (601)             (601)
Change in cumulative foreign currency translation adjustment 6 6       6    
Change in fair value of cash flow hedge, net of taxes (18,764) (18,764)       (18,764)    
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes 1,861 1,861       1,861    
Net (loss) income (12,734) (20,797)         (20,797) 8,063
Ending balance (in shares) at Sep. 30, 2020     51,596,098          
Ending balance, value at Sep. 30, 2020 246,121 157,205 $ 5   306,079 (24,923) (123,956) 88,916
Beginning balance (in shares) at Jun. 30, 2020     51,554,760          
Beginning balance, value at Jun. 30, 2020 233,256 147,808 $ 5   304,012 (26,098) (130,111) 85,448
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of common stock upon exercise of options 0              
Issuance of common stock under the equity compensation plan (in shares)     37,000 4,338        
Stock-based compensation expense 2,067 2,067     2,067      
Purchase of noncontrolling interests by third party (601)             (601)
Change in cumulative foreign currency translation adjustment 11 11       11    
Change in fair value of cash flow hedge, net of taxes 195 195       195    
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes 969 969       969    
Other (1) (1)         (1)  
Net (loss) income 10,225 6,156         6,156 4,069
Ending balance (in shares) at Sep. 30, 2020     51,596,098          
Ending balance, value at Sep. 30, 2020 246,121 157,205 $ 5   306,079 (24,923) (123,956) 88,916
Beginning balance (in shares) at Dec. 31, 2020     51,640,537          
Beginning balance, value at Dec. 31, 2020 258,303 165,743 $ 5   307,788 (24,051) (117,999) 92,560
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of common stock upon exercise of options (in shares)     2,500          
Issuance of common stock upon exercise of options 26 26     26      
Issuance of common stock under the equity compensation plan (in shares)     1,127,996 466,490        
Stock-based compensation expense 21,608 21,608     21,608      
Issuance of common stock for sale of unregistered securities for acquisition (in shares)     67,658          
Issuance of common stock for sale of unregistered securities for acquisition 2,025 2,025     2,025      
Forfeiture of restricted stock (in shares)     (3,365)          
Forfeiture of restricted stock (42) (42)     (42)      
Sale of economic interests in majority owned subsidiary, net of taxes 11,602 4,198     4,198     7,404
Purchase of noncontrolling interests by third party (4) (4)     (4)     0
Contribution from noncontrolling partner 123             123
Change in cumulative foreign currency translation adjustment (32) (32)       (32)    
Change in fair value of cash flow hedge, net of taxes 14,149              
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes 2,765 2,765       2,765    
Other 0         1 (1)  
Net (loss) income 43,005 28,550         28,550 14,455
Ending balance (in shares) at Sep. 30, 2021     53,301,816          
Ending balance, value at Sep. 30, 2021 339,379 224,837 $ 5   335,599 (21,317) (89,450) 114,542
Beginning balance (in shares) at Jun. 30, 2021     52,678,030          
Beginning balance, value at Jun. 30, 2021 299,279 197,064 $ 5   324,954 (22,227) (105,668) 102,215
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of common stock under the equity compensation plan (in shares)     94,638 464,855        
Stock-based compensation expense 4,463 4,463     4,463      
Issuance of common stock for sale of unregistered securities for acquisition (in shares)     67,658          
Issuance of common stock for sale of unregistered securities for acquisition 2,025 2,025     2,025      
Forfeiture of restricted stock (in shares)     (3,365)          
Forfeiture of restricted stock (42) (42)     (42)      
Sale of economic interests in majority owned subsidiary, net of taxes 11,602 4,198     4,198     7,404
Change in cumulative foreign currency translation adjustment (11) (11)       (11)    
Change in fair value of cash flow hedge, net of taxes 2,870              
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes 920 920       920    
Other (1)       1 1 (2) (1)
Net (loss) income 21,144 16,220         16,220 4,924
Ending balance (in shares) at Sep. 30, 2021     53,301,816          
Ending balance, value at Sep. 30, 2021 $ 339,379 $ 224,837 $ 5   $ 335,599 $ (21,317) $ (89,450) $ 114,542